• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Mersana Therapeutics Inc.

    4/30/25 11:23:39 AM ET
    $MRSN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRSN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Mersana Therapeutics Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    59045L106

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    59045L106


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    69,658.00
    7Sole Dispositive Power

    8,273,385.00
    8Shared Dispositive Power

    104,382.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    8,377,767.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.72 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Mersana Therapeutics Inc
    (b)Address of issuer's principal executive offices:

    840 Memorial Drive, Cambridge, MA, 02139
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd., Malvern, PA 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    59045L106
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    8377767
    (b)Percent of class:

    6.72  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    69658

     (iii) Sole power to dispose or to direct the disposition of:

    8273385

     (iv) Shared power to dispose or to direct the disposition of:

    104382

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:04/30/2025
    Get the next $MRSN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $MRSN

    DatePrice TargetRatingAnalyst
    2/6/2025Outperform
    William Blair
    11/15/2024$5.00Buy
    Citigroup
    3/19/2024$5.00Underweight → Neutral
    JP Morgan
    2/29/2024$6.00Neutral → Buy
    BTIG Research
    2/29/2024$7.00Neutral → Buy
    Guggenheim
    2/29/2024$2.00 → $7.00Neutral → Outperform
    Wedbush
    12/4/2023$1.00 → $5.00Neutral → Buy
    Citigroup
    7/28/2023$7.00 → $1.00Outperform → Neutral
    Robert W. Baird
    More analyst ratings

    $MRSN
    SEC Filings

    See more
    • Mersana Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement

      8-K - Mersana Therapeutics, Inc. (0001442836) (Filer)

      7/3/25 4:10:34 PM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mersana Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Mersana Therapeutics, Inc. (0001442836) (Filer)

      6/13/25 4:22:01 PM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mersana Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Mersana Therapeutics, Inc. (0001442836) (Filer)

      6/2/25 8:23:21 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRSN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Alleva Lawrence M

      4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)

      6/13/25 5:15:12 PM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Hack Andrew A. F.

      4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)

      6/13/25 5:10:40 PM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Dere Willard H

      4 - Mersana Therapeutics, Inc. (0001442836) (Issuer)

      6/13/25 5:02:42 PM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRSN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting

      31% confirmed ORR (8 responses in 26 evaluable patients) across B7-H4 high tumors at intermediate doses 44% confirmed ORR (7 responses in 16 evaluable patients) in the subset of patients with ≤4 prior lines of therapy CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced additional interim Phase 1 clinical data for emiltatug ledadotin (Emi-Le; XMT-1660), the company's B7-H4-directed Dolasynthen ADC. These data are being presented in an oral session today at the American Socie

      6/2/25 8:10:31 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mersana Therapeutics to Present at Upcoming Investor Conferences

      CAMBRIDGE, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will participate in the following upcoming investor events: TD Cowen 6th Annual Oncology Innovation SummitFormat:         Fireside chatDate/Time:   Tuesday, May 27, 2025, at 2:00 p.m. Eastern TimeGoldman Sachs 46th Annual Global Healthcare Conference Format:        PresentationDate/Time:  Monday, June 9, 2025, at 2:00 p.m. Eastern Time Live webcasts of these events will be available on the I

      5/20/25 8:00:59 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

      In a release issued under the same headline earlier today by Mersana Therapeutics, Inc. (NASDAQ:MRSN), please note that there was a transcription error in the last cell of the first table. The Median OS should have been 5.7 months rather than 1.7 months. The corrected release follows: Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results Updated clinical data from Emi-Le Phase 1 dose escalation and backfill cohorts presented today at ESMO Breast Cancer 2025 ORR increased to 31% across tumor types among evaluable patients with B7-H4 high tumors receiving intermediate dosesEncouraging preliminary time-to-event data in triple-negative breast cancer (

      5/15/25 9:20:09 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRSN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Mersana Therapeutics

      William Blair initiated coverage of Mersana Therapeutics with a rating of Outperform

      2/6/25 7:08:59 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citigroup resumed coverage on Mersana Therapeutics with a new price target

      Citigroup resumed coverage of Mersana Therapeutics with a rating of Buy and set a new price target of $5.00

      11/15/24 8:15:56 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mersana Therapeutics upgraded by JP Morgan with a new price target

      JP Morgan upgraded Mersana Therapeutics from Underweight to Neutral and set a new price target of $5.00

      3/19/24 7:51:31 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRSN
    Leadership Updates

    Live Leadership Updates

    See more
    • Mersana Therapeutics Announces Changes in Leadership

      Anna Protopapas to retire as President and Chief Executive Officer (CEO); will remain a member of the Board of DirectorsMartin Huber, M.D., current member of the Board of Directors, to be named President and CEOBrian DeSchuytner named Chief Operating Officer; Mohan Bala, Ph.D., named Chief Development Officer CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the retirement of Anna Protopapas, President and CEO, effective September 10, 2023, and the

      9/6/23 7:00:40 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mersana Therapeutics Provides Statement About SVB

      CAMBRIDGE, Mass., March 10, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided an update about its capital resources. A de minimis amount of Mersana's capital is currently held in a checking account at Silicon Valley Bank (SVB). The balance of the company's capital resources is held in a custodial account managed by another institution and in money market funds of institutions other than SVB. Mersana has a loan and security agreement with Oxford Finance LLC and SVB. As previously

      3/10/23 7:10:38 PM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mersana Therapeutics Announces Appointment of Mohan Bala, Ph.D., as SVP, Strategic Product Planning & Program Leadership

      CAMBRIDGE, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the appointment of Mohan Bala, Ph.D., as SVP, Strategic Product Planning & Program Leadership, effective Monday, October 25, 2021. Dr. Bala will assume strategic product planning responsibilities from Brian DeSchuytner who has been named SVP and Chief Financial Officer. Mr. DeSchuytner will continue to lead finance, business development, corporate strategy and investor relations and remain Mersana's pri

      10/25/21 8:00:00 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRSN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Mersana Therapeutics Inc.

      SC 13D/A - Mersana Therapeutics, Inc. (0001442836) (Subject)

      11/15/24 4:45:57 PM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mersana Therapeutics Inc.

      SC 13G/A - Mersana Therapeutics, Inc. (0001442836) (Subject)

      11/14/24 5:45:55 PM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mersana Therapeutics Inc.

      SC 13G/A - Mersana Therapeutics, Inc. (0001442836) (Subject)

      11/14/24 6:01:51 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRSN
    Financials

    Live finance-specific insights

    See more
    • CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

      In a release issued under the same headline earlier today by Mersana Therapeutics, Inc. (NASDAQ:MRSN), please note that there was a transcription error in the last cell of the first table. The Median OS should have been 5.7 months rather than 1.7 months. The corrected release follows: Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results Updated clinical data from Emi-Le Phase 1 dose escalation and backfill cohorts presented today at ESMO Breast Cancer 2025 ORR increased to 31% across tumor types among evaluable patients with B7-H4 high tumors receiving intermediate dosesEncouraging preliminary time-to-event data in triple-negative breast cancer (

      5/15/25 9:20:09 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

      Updated clinical data from Emi-Le Phase 1 dose escalation and backfill cohorts presented today at ESMO Breast Cancer 2025 ORR increased to 31% across tumor types among evaluable patients with B7-H4 high tumors receiving intermediate dosesEncouraging preliminary time-to-event data in triple-negative breast cancer (TNBC) Second, higher dose recently selected for expansion in post-topoisomerase-1 inhibitor ADC (post-topo-1) TNBC; patient enrollment advancing in both dose expansion cohorts Plan to report initial clinical data from expansion in second half of 2025Conference call today at 8:00 a.m. ET CAMBRIDGE, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a

      5/15/25 7:00:40 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer

      Cost-saving initiatives expected to extend company's cash runway and support current operating plan commitments into mid-2026 Company to host conference call at 8:00 a.m. ET on May 15 to discuss business updates and first quarter 2025 financial results CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the implementation of a strategic restructuring and reprioritization plan aimed at extending the company's cash runway and furthering the development of emiltatug ledad

      5/6/25 7:00:51 AM ET
      $MRSN
      Biotechnology: Pharmaceutical Preparations
      Health Care